Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

Search Results

9,077 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Results By Year timeline is not available.
Page 1
Dorzagliatin add-on therapy to metformin in patients with type 2 diabetes: a randomized, double-blind, placebo-controlled phase 3 trial.
Yang W, Zhu D, Gan S, Dong X, Su J, Li W, Jiang H, Zhao W, Yao M, Song W, Lu Y, Zhang X, Li H, Wang G, Qiu W, Yuan G, Ma J, Li W, Li Z, Wang X, Zeng J, Yang Z, Liu J, Liang Y, Lu S, Zhang H, Liu H, Liu P, Fan K, Jiang X, Li Y, Su Q, Ning T, Tan H, An Z, Jiang Z, Liu L, Zhou Z, Zhang Q, Li X, Shan Z, Xue Y, Mao H, Shi L, Ye S, Zhang X, Sun J, Li P, Yang T, Li F, Lin J, Zhang Z, Zhao Y, Li R, Guo X, Yao Q, Lu W, Qu S, Li H, Tan L, Wang W, Yao Y, Chen D, Li Y, Gao J, Hu W, Fei X, Wu T, Dong S, Jin W, Li C, Zhao D, Feng B, Zhao Y, Zhang Y, Li X, Chen L. Yang W, et al. Among authors: zeng j. Nat Med. 2022 May;28(5):974-981. doi: 10.1038/s41591-022-01803-5. Epub 2022 May 12. Nat Med. 2022. PMID: 35551292 Free PMC article. Clinical Trial.
[The design and baseline characteristics of a phase III study to evaluate the efficacy and safety of alogliptin versus placebo in type 2 diabetes mellitus in Mainland China].
Pan CY, Li WH, Zeng JE, Li CJ, Yang JK, Ji QH, Lu JM, Lü XF, Li XF, Qu S, Xu XJ, Xue YM, Li L, Jiang ZS, Zheng BZ, Bu RF, Han P, Liu Y, Liu JD, Peng YD, Liu XM, Liu ZM, Yan L, Lei MX, Li XJ, Song QH, Shi BY, Gu W, Li ZF. Pan CY, et al. Zhonghua Nei Ke Za Zhi. 2013 Nov;52(11):932-5. Zhonghua Nei Ke Za Zhi. 2013. PMID: 24439186 Clinical Trial. Chinese.
[Efficacy and safety of alogliptin in treatment of type 2 diabetes mellitus: a multicenter, randomized, double-blind, placebo-controlled phase III clinical trial in mainland China].
Pan C, Li W, Zeng J, Li C, Yang J, Ji Q, Lu J, Lyu X, Li X, Qu S, Xu X, Xue Y, Li L, Jiang Z, Zheng B, Bu R, Han P, Liu Y, Liu J, Peng Y, Liu X, Liu Z, Yan L, Lei M, Li X, Song Q, Shi B, Gu W, Li Z. Pan C, et al. Among authors: zeng j. Zhonghua Nei Ke Za Zhi. 2015 Nov;54(11):949-53. Zhonghua Nei Ke Za Zhi. 2015. PMID: 26759214 Clinical Trial. Chinese.
Comparative effectiveness of metformin monotherapy in extended release and immediate release formulations for the treatment of type 2 diabetes in treatment-naïve Chinese patients: Analysis of results from the CONSENT trial.
Ji L, Liu J, Yang J, Li Y, Liang L, Zhu D, Li Q, Ma T, Xu H, Yang Y, Zeng J, Feng B, Qu S, Li Y, Ma L, Lin S, Wang J, Li W, Song W, Li X, Luo Y, Xi S, Lin M, Liu Y, Liang Z. Ji L, et al. Among authors: zeng j. Diabetes Obes Metab. 2018 Apr;20(4):1006-1013. doi: 10.1111/dom.13190. Epub 2018 Jan 22. Diabetes Obes Metab. 2018. PMID: 29227571 Clinical Trial.
Dorzagliatin monotherapy in Chinese patients with type 2 diabetes: a dose-ranging, randomised, double-blind, placebo-controlled, phase 2 study.
Zhu D, Gan S, Liu Y, Ma J, Dong X, Song W, Zeng J, Wang G, Zhao W, Zhang Q, Li Y, Fang H, Lv X, Shi Y, Tian H, Ji L, Gao X, Zhang L, Bao Y, Lei M, Li L, Zeng L, Li X, Hou X, Zhao Y, Hu T, Ge X, Zhao G, Li Y, Zhang Y, Chen L. Zhu D, et al. Among authors: zeng l, zeng j. Lancet Diabetes Endocrinol. 2018 Aug;6(8):627-636. doi: 10.1016/S2213-8587(18)30105-0. Epub 2018 May 4. Lancet Diabetes Endocrinol. 2018. PMID: 29735394 Clinical Trial.
Phase III, randomized, double-blind, placebo-controlled study to evaluate the efficacy and safety of teneligliptin monotherapy in Chinese patients with type 2 diabetes mellitus inadequately controlled with diet and exercise.
Ji L, Ma J, Lu W, Liu J, Zeng J, Yang J, Li W, Zhang X, Xiao X, Takayanagi G, Wang Y. Ji L, et al. Among authors: zeng j. J Diabetes Investig. 2021 Apr;12(4):537-545. doi: 10.1111/jdi.13389. Epub 2020 Sep 20. J Diabetes Investig. 2021. PMID: 32810383 Free PMC article. Clinical Trial.
Exenatide Twice Daily Plus Glargine Versus Aspart 70/30 Twice Daily in Patients With Type 2 Diabetes With Inadequate Glycemic Control on Premixed Human Insulin and Metformin.
Chen X, Xu Y, Zhang J, Shao S, Duan Y, Liu P, Shen L, Zhang J, Zeng J, Lin M, Zhao S, Ma J, Zhao T, Hu J, Liao Y, Chen X, Hu S, Xue Y, Zeng Z, He W, Liu Z, Li W, Liu L, Yin P, Yu X. Chen X, et al. Among authors: zeng j, zeng z. Endocr Pract. 2021 Aug;27(8):790-797. doi: 10.1016/j.eprac.2021.03.015. Epub 2021 Apr 6. Endocr Pract. 2021. PMID: 33831552 Clinical Trial.
Dorzagliatin in drug-naïve patients with type 2 diabetes: a randomized, double-blind, placebo-controlled phase 3 trial.
Zhu D, Li X, Ma J, Zeng J, Gan S, Dong X, Yang J, Lin X, Cai H, Song W, Li X, Zhang K, Zhang Q, Lu Y, Bu R, Shao H, Wang G, Yuan G, Ran X, Liao L, Zhao W, Li P, Sun L, Shi L, Jiang Z, Xue Y, Jiang H, Li Q, Li Z, Fu M, Liang Z, Guo L, Liu M, Xu C, Li W, Yu X, Qin G, Yang Z, Su B, Zeng L, Geng H, Shi Y, Zhao Y, Zhang Y, Yang W, Chen L. Zhu D, et al. Among authors: zeng l, zeng j. Nat Med. 2022 May;28(5):965-973. doi: 10.1038/s41591-022-01802-6. Epub 2022 May 12. Nat Med. 2022. PMID: 35551294 Clinical Trial.
9,077 results